Rostra Therapeutics
Anti-infective platform with the power to restore health and save lives, globally. We are changing the paradigm for fighting infectious disease by developing a multi-targeted approach to treat serious infections caused by viruses, fungi, bacteria and parasites.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Rostra Therapeutics is a pioneering biotech startup focused on developing innovative medicines to combat infectious diseases, which claim over 15 million lives globally each year. The company is a spin-out from the University of Strathclyde, leveraging cutting-edge drug discovery technology from the Department of Pure and Applied Chemistry and the Strathclyde Institute of Pharmacy and Biomedical Science.
Rostra Therapeutics specializes in the development of second-generation S-MGBs (small molecule gene regulators), which have the potential to become crucial in the fight against infectious diseases. The company’s primary goal in the short to medium term is to optimize these molecules, advance them through pre-IND (Investigational New Drug) stages, and move them into Phase I clinical trials.
The company operates in the pharmaceutical and biotechnology market, serving patients and clinicians who are in urgent need of novel treatments for infectious diseases. By focusing on this niche, Rostra Therapeutics aims to address a significant unmet medical need, thereby positioning itself as a key player in the global healthcare landscape.
Rostra’s business model is built around a small, focused core team of three scientists and two commercial leaders, supported by a virtual network of experts. This lean structure allows the company to efficiently develop its novel medicines while keeping operational costs low. Revenue generation is expected to come from the successful development and commercialization of its drug candidates, either through direct sales, partnerships, or licensing agreements with larger pharmaceutical companies.
In summary, Rostra Therapeutics is a forward-thinking biotech company dedicated to developing life-saving medicines for infectious diseases, leveraging innovative technology and a focused, efficient team structure to bring these treatments to market.
Keywords: biotech, infectious diseases, drug discovery, S-MGBs, University of Strathclyde, clinical trials, pharmaceutical, healthcare, innovation, commercialization.